RNAC Q3 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-7.75

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$40M

Total Liabilities

$44M

Stockholders' Equity

-$5M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$16M	+26.0%
Net Income	-$12M	-$16M	+25.0%